Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Perkins

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Ejhaem|February 26, 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosisStephen T Oh, Srdan Verstovsek, Vikas Gupta, et al.
Cellular and Molecular Gastroenterology and Hepatology|October 9, 2025
Pathogenic OTUD3 Mutations Predispose to Ulcerative Colitis Due to Barrier DysfunctionRabina Giri, Minyi Lee, Graham W Magor, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Future Oncology (London, England)|January 11, 2021
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemicSrdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, et al.
Nature Communications|June 17, 2020
Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemiaTherese Vu, Jasmin Straube, Amy H Porter, et al.
Cancer Medicine|April 6, 2023
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studiesRuben A Mesa, Stacie Hudgens, Lysbeth Floden, et al.
Internal Medicine Journal|July 25, 2022
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer CentreConstantine S Tam, Gareth P Gregory, Matthew Ku, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
The Lancet. Haematology|July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 studyAaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Ejhaem|February 26, 2024
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosisStephen T Oh, Srdan Verstovsek, Vikas Gupta, et al.
Cellular and Molecular Gastroenterology and Hepatology|October 9, 2025
Pathogenic OTUD3 Mutations Predispose to Ulcerative Colitis Due to Barrier DysfunctionRabina Giri, Minyi Lee, Graham W Magor, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Future Oncology (London, England)|January 11, 2021
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemicSrdan Verstovsek, Chih-Cheng Chen, Miklós Egyed, et al.
Nature Communications|June 17, 2020
Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemiaTherese Vu, Jasmin Straube, Amy H Porter, et al.
Cancer Medicine|April 6, 2023
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studiesRuben A Mesa, Stacie Hudgens, Lysbeth Floden, et al.
Internal Medicine Journal|July 25, 2022
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer CentreConstantine S Tam, Gareth P Gregory, Matthew Ku, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
The Lancet. Haematology|July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 studyAaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
Pageof 5